---
figid: PMC11010004__JAH3-13-e032031-g002
pmcid: PMC11010004
image_filename: JAH3-13-e032031-g002.jpg
figure_link: /pmc/articles/PMC11010004/figure/jah39200-fig-0003/
number: Figure 3
figure_title: A pathway for managing patients with FH or ASCVD, or at risk of ASCVD,
  adapted from the UK NHS pathway and ACC ECDP.,
caption: '*ACS, history of MI, stable/unstable angina, coronary or other arterial
  revascularization, stroke, TIA, or PAD; †History of multiple major cardiovascular
  events (ACS [past 12 months], history of MI, ischemic stroke, symptomatic PAD),
  or a major cardiovascular event plus high‐risk conditions (≥65 years of age, heterozygous
  FH, history of coronary artery bypass, diabetes, hypertension, chronic kidney disease,
  smoking, LDL‐C ≥100 mg/dL despite maximally tolerated LLT, history of congestive
  heart failure); ‡Intolerant of ≥2 statins with 1 attempt at lowest recommended dose;
  §Increase to 150 mg Q2W if required; ‖At 12 weeks increase to 420 mg Q2W, if required.
  ACC indicates American College of Cardiology; ACS, acute coronary syndrome; ASCVD,
  atherosclerotic cardiovascular disease; ECDP, Expert Consensus Decision Pathway;
  FH, familial hypercholesterolemia; LDL‐C, low‐density lipoprotein cholesterol; LLT,
  lipid‐lowering therapy; MI, myocardial infarction; NHS, National Health Service;
  PAD, peripheral arterial disease; PCSK9, proprotein convertase subtilisin/kexin
  type 9; Q2W, every 2 weeks; Q4W, every 4 weeks; SASE, statin‐associated side effect;
  SC, subcutaneously; TIA, transient ischemic attack; and UK, United Kingdom.'
article_title: 'Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside
  Story of Inclisiran.'
citation: Michael J. Wilkinson, et al. J Am Heart Assoc. 2024 Mar 19;13(6):e032031.
year: '2024'

doi: 10.1161/JAHA.123.032031
journal_title: 'Journal of the American Heart Association: Cardiovascular and Cerebrovascular
  Disease'
journal_nlm_ta: J Am Heart Assoc
publisher_name: John Wiley and Sons Inc.

keywords:
- atherosclerotic cardiovascular disease
- inclisiran
- low‐density lipoprotein cholesterol
- proprotein convertase subtilisin/kexin type 9
- small interfering RNA
- Atherosclerosis

---
